Catalent

What Catalent does

Catalent is a global Contract Development and Manufacturing Organization (CDMO) serving pharmaceutical, biotechnology, and consumer health companies across the full drug lifecycle, from early-stage development through commercial manufacturing and clinical supply. The company's portfolio spans oral dose (including RP Scherer Softgel, OptiForm, spray drying, and micronization technologies), biologics (GPEX cell line development, SMARTag bioconjugation, OneBio integrated suite), cell therapy (autologous/allogeneic CAR-T, iPSC-derived therapies via the RheinCell platform, NK cells), gene therapy (UpTempo AAV and plasmid DNA manufacturing at commercial scale), specialty (inhalation, small molecule injectables), clinical supply services (OneHub portal, FastChain demand-led supply, FlexDirect direct-to-patient, CTSuccess planning), and self-care/consumer health (OTC, supplements, beauty). Catalent operates from more than 45 facilities across North America, Europe, Asia Pacific, and Latin America, with notable campuses at Harmans, Maryland (gene therapy), Princeton (cell therapy), Kansas City (biologics analytical and clinical supply), Morrisville/RTP (inhalation), Madison (mammalian cell line), and Gosselies, Belgium (cell therapy and plasmid DNA).

The business model is B2B professional services revenue earned through contract development, manufacturing, and supply agreements — quote-based pricing determined by project scope, complexity, scale, and contract length, with multi-year terms for commercial manufacturing and project-based engagement for clinical work. Catalent commercializes a set of proprietary technology platforms (GPEX, UpTempo, SMARTag, OptiForm, OneBio, iPSC, Qai) that differentiate its offering versus pure-play contract manufacturers. The company sells directly to enterprise customers through technical sales, scientific consultation, and strategic partnership agreements, supported by industry conference participation and thought leadership content. Approximately 2,400 of its ~15,000 employees are scientists and technicians.

Catalent was acquired by Novo Holdings A/S for $16.5 billion in December 2024, taking it private after years as a publicly traded NYSE-listed company under ticker CTLT. Ownership has shifted strategic emphasis toward fill-finish and prefilled syringe capacity for GLP-1 therapies, while the business has simultaneously undergone restructuring in cell and gene therapy — including layoffs at the Harmans, Maryland gene therapy plant and the announced closure of the Gosselies, Belgium cell therapy site — and has faced FDA regulatory scrutiny at the Catalent Indiana fill-finish facility that has delayed customer approvals. Leadership includes CEO Alessandro Maselli and CFO Matti Masanovich.

Name

Catalent

Legal name

Catalent, Inc.

Website

https://catalent.com

Company type

Private

Founded year

1933

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Catalent is a global CDMO providing drug development, manufacturing, and clinical supply services across oral dose, biologics, cell therapy, gene therapy, injectables, and consumer health, serving pharma, biotech, and wellness companies from 45+ facilities worldwide. Privately held by Novo Holdings A/S since December 2024.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Cell Therapy CDMO (HLAGABAD), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ)

Keywords

• Contract development manufacturing
• Pharmaceutical CDMO services
• Biologics manufacturing
• Cell gene therapy
• Clinical supply services

Headquarters

HQ city

Tampa

HQ country

United States

HQ region

North America

Offices14 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain

Revenue model

1. Contract Development and Manufacturing Services: Catalent generates revenue through providing integrated CDMO services including drug substance manufacturing, drug product manufacturing, fill-finish services, clinical supply services, and commercial manufacturing. Services are provided on a project basis with long-term contracts for commercial manufacturing.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Catalent is a global Contract Development and Manufacturing Organization (CDMO) that provides integrated pharmaceutical development, manufacturing, and clinical supply services across oral dose, biologics, cell therapy, gene therapy, specialty, and consumer health modalities. The company partners with pharma, biotech, and self-care innovators from early-stage development through commercial manufacturing, leveraging proprietary technology platforms such as GPEx, UpTempo, SMARTag, OptiForm, and iPSC. Services span drug substance and drug product manufacturing, fill-finish, clinical packaging and supply, regulatory support, and tech transfers across a network of 45+ facilities globally.

Product overview

Catalent is a leading global Contract Development and Manufacturing Organization (CDMO) offering an integrated portfolio of pharma services organized around five core business units: Pharma Services (oral dose, biologics, specialty), Clinical Supply Services, and Self-Care/Consumer Health. The Pharma Services unit includes oral dosage development and manufacturing via OptiForm Solution Suite and Softgel Technologies; biologics development through OneBio Suite combining GPEx cell line development, drug substance manufacturing, and drug product fill-finish; and cell/gene therapy manufacturing leveraging iPSC, UpTempo plasmid DNA, and SMARTag bioconjugation platforms. Clinical Supply Services provides end-to-end clinical trial support including FastChain demand-led supply, FlexDirect direct-to-patient distribution, CTSuccess planning, and Case Management for advanced therapies, accessible through the OneHub digital portal. Specialty services cover inhalation and small molecule injectables. Qai represents the company's first enterprise AI deployment for quality management.

Differentiator

Problem solved

Functional benefit

Brands

• OptiForm Total Supply: Integrated development, manufacturing and clinical supply solution combining formulation, clinical manufacturing, forecasting, packaging, labeling, storage and distribution.
• OneHub Portal
• FastChain Demand Led Supply
• FlexDirect
• CTSuccess
• OptiForm Solution Suite
• OneBio Suite
• GPEx
• SMARTag
• UpTempo
• Qai
• OneXpress Solution
• OptiDose Design Solution
• Portfolio Accelerator

Products and services

• Pharma Services Integrated CDMO solutions spanning oral dose, biologics, specialty and clinical supply. Services include tech transfers, commercial manufacturing, and regulatory support for pharmaceutical and biotech innovators.
• Oral Dose Comprehensive oral dosage solutions including development, bioavailability enhancement, dose form design, manufacturing and analytical services for tablets, capsules, softgel, and orally disintegrating formats.
• Biologics End-to-end biologics development and manufacturing including cell line development, process development, drug substance and drug product manufacturing, and analytical services.
• Cell Therapy GMP manufacturing and development services for autologous and allogeneic cell therapies including CAR-T, NK cells, and iPSC-derived cell products, with commercial-scale manufacturing capabilities.
• Gene Therapy Viral vector manufacturing and development services for AAV, lentiviral vectors, and gene therapies, including plasmid DNA manufacturing, process development, and GMP commercial manufacturing.
• Clinical Supply Services Global clinical supply management including packaging, labeling, storage, distribution, cold chain services, and comparator sourcing for Phase I-IV clinical trials.
• Self-Care (Consumer Health) Contract manufacturing for OTC products, dietary supplements, and beauty/personal care products including formulation, manufacturing, and packaging services.
• Specialty (Inhalation and Injectables) Specialized delivery solutions including inhalation products (dry powder inhalers, nasal delivery) and small molecule injectables with advanced containment technologies.
• OptiForm Total Supply Integrated development, manufacturing and clinical supply solution combining formulation, clinical manufacturing, forecasting, packaging, labeling, storage and distribution in a parallel approach.
• OneHub Portal Customer portal providing visibility into clinical supply operations including production timelines, inventory alerts, shipment tracking, and document management with secure sharing capabilities.
• FastChain Demand Led Supply Dynamic decentralized approach to secondary packaging, labeling and distribution of made-to-order patient kits based on actual site/patient demand with Pack to Stock, Pack to Order, and Hybrid models.
• FlexDirect Direct-to-Patient Services Clinical supply services enabling direct shipment of investigational products to patients' homes, reducing need for in-person site visits through site-to-patient and pharmacy-direct models.
• Case Management Services End-to-end supply chain coordination for cell and gene therapies including scheduling, shipment arrangement, chain of custody documentation, and 24/7 monitoring.
• CTSuccess Clinical Supply Planning Clinical supply planning service using proprietary StartScore methodology to evaluate project complexity and provide tailored support for study execution.
• Qai Enterprise AI-powered quality management tool integrating into existing quality workflows to accelerate root cause analysis, reduce repeat deviations, and improve reporting consistency across global manufacturing.

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature9 records

Partnerships

Five partnerships are on record, tiered core.

• CarthericscoreStrategic or Co-development Partner · 18 June 2026Expanded agreement for iPSC-derived CAR-NK cell therapies, strengthening Catalent's position in cell therapy manufacturing services.
• Silexion TherapeuticscoreStrategic or Co-development Partner · 13 May 2026Partnership for GMP clinical batch manufacturing of SIL204, next-generation siRNA therapy targeting mutated KRAS, at Catalent's facility in Limoges, France for Phase 2/3 trial in locally advanced pancreatic cancer.
• CarthericscoreStrategic or Co-development Partner · 9 April 2026Expanded partnership through amended commercial license agreement allowing Cartherics to use Catalent's cGMP-compliant iPSC line for manufacturing and commercializing CAR-NK cell therapies for cancer and endometriosis, including lead candidate CTH-401. Cartherics received FDA approval to use this cell line.
• GelMEDIXcoreStrategic or Co-development Partner · 31 March 2026Global partnership for development and clinical manufacturing of iPSC-derived cell therapies targeting ocular and retinal diseases. Catalent provides GMP-compliant iPSC lines and manufacturing capabilities to support GelMEDIX's vision-restoring therapies through all clinical stages.
• S.BiomedicscoreStrategic or Co-development Partner · 18 February 2026Strategic partnership to develop and manufacture TED-A9, a cell therapy for Parkinson's disease. Catalent utilizes its global capabilities in cell therapy development and GMP manufacturing to support S.Biomedics' pipeline from early development through clinical trials and market launch.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Lonza Group: Largest pure-play global CDMO offering biologics, cell & gene therapy, and small-molecule manufacturing across a comparable multi-modality footprint; competes head-to-head with Catalent in mammalian cell line, viral vector and oral dose services.
• Samsung Biologics: Korean large-mammalian biologics CDMO with massive single-site bioreactor capacity; competes directly with Catalent Biologics for mAb and recombinant protein programs from clinical through commercial supply.
• WuXi Biologics: Global biologics CDMO offering end-to-end services from cell line development to commercial manufacturing; competes with Catalent's OneBio Suite and GPEx cell line offering, particularly for Asia-Pacific and cost-sensitive programs.
• Siegfried Holding: Swiss CDMO specializing in oral solid dose APIs and drug products; competes directly with Catalent's Oral Dose business in small-molecule formulation and manufacturing.
• Recipharm: European CDMO focused on oral solid dose, sterile fill-finish and biologics; competes with Catalent's European footprint across small-molecule and aseptic manufacturing services.
• PCI Pharma Services: Global CDMO focused on clinical trial supply, commercial packaging and sterile fill-finish; directly overlaps Catalent's Clinical Supply Services and specialty/injectables offerings.
• Vetter Pharma: Specialist CDMO for aseptic fill-finish of injectables and pre-filled syringes; directly competes with Catalent's sterile fill-finish and specialty injectable offerings, particularly for biologics and GLP-1 customers.

Broad incumbents

• Thermo Fisher Scientific (Patheon CDMO): Operates one of the largest pharma services franchises globally via Patheon, covering drug substance, drug product, clinical supply and packaging; overlaps Catalent's integrated offering but sits within a much larger diversified life-sciences portfolio.
• IQVIA (Q² Solutions / Manufacturing Services): Diversified life-sciences services company with pharma manufacturing exposure through Q² Solutions and broader clinical/commercial services; partial overlap with Catalent's clinical supply and biologics analytics offerings.

Emerging players

• Charles River Laboratories: Primarily a CRO/preclinical services firm but expanding into cell & gene therapy CDMO via its CDMO segment; competes with Catalent's CGT offerings in early-stage and clinical manufacturing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/catalentpharma
• YouTubeyoutube.com/user/catalent
• Facebookfacebook.com/CatalentPharmaSolutions
• LinkedInlinkedin.com/company/catalent-pharma-solutions
• Instagraminstagram.com/catalent

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Catalent